GH: Shield’s rapid scale-up, cost reductions, and broad coverage drive strong growth and market leadership
Q2 saw strong revenue and volume growth, with Shield now covering 80% of eligible patients and significant cost reductions underway. Guardant360 and Reveal platforms are expanding clinical use cases, while commercial wins and product innovation position the company for continued growth.Based on Gua…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.